A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Enrolling by invitation · Phase 1
Conditions studied: Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathy
In brief
This study will have two Phases: Phase 1a and Phase 1b. The goal of this clinical study is to learn more about the study drug KITE-363, to establish dosing, tolerability, safety, and preliminary efficacy of KITE-363 in participants with refractory autoimmune diseases. The primary objectives of this study are: Phase 1a: To evaluate the safety and tolerability of KITE-363 in participants with autoimmune disease. To determine the recommended dose for Phase 1b. Phase 1b: To evaluate the safety and efficacy of KITE-363 in participants with autoimmune disease.
Key facts
- Study ID
- NCT07038447
- Run by
- Kite, A Gilead Company
- People needed
- 52
- Starts
- 2025-07-02
- Expected to finish
- 2029-07-01
- Last updated by the study team
- 2026-06-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- Stanford University — Stanford, California, United States
- Tampa General Hospital Cancer Institute — Tampa, Florida, United States
- Icahn School of Medicine at Mount Sinai — New York, New York, United States
- Concord Repatriation General Hospital — Syndey, New South Wales, Australia
- St Vincent's Hospital — Fitzroy, Victoria, Australia
- Jewish General Hospital — Montreal, Canada
- The Ottawa Hospital, General Campus — Ottawa, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.